Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Receptor pharmacology.

Andrew Young1

  • 1Amylin Pharmaceuticals, Inc., San Diego, California, USA.

Advances in Pharmacology (San Diego, Calif.)
|February 24, 2006
PubMed
Summary
This summary is machine-generated.

Researchers identified amylin receptors by discovering receptor activity modifying proteins (RAMPs) that associate with calcitonin receptors. This explains amylin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remote sensing data and machine learning models estimate sorghum grain yield in a plant breeding program.

Plant phenomics (Washington, D.C.)·2026
Same author

Safety, immunogenicity, and dose ranging of a bivalent respiratory syncytial virus and human metapneumovirus glycoprotein F-molecular clamp vaccine candidate in older adults: 1-month interim analysis of an ongoing randomised, observer-blind, placebo- and active-controlled, phase 1 trial.

Vaccine·2026
Same author

Stepwise loss of complexity in hagfish eyes prior to deep sea colonization.

Biology letters·2026
Same author

Viral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state.

Communications biology·2026
Same author

Physiological and Yield Responses of Peanut (<i>Arachis hypogaea</i> L.) Genotypes Under Well-Watered and Water-Stressed Conditions.

Plants (Basel, Switzerland)·2026
Same author

Nerve Combing for Idiopathic Trigeminal Neuralgia Without Neurovascular Compression.

Journal of clinical and experimental dentistry·2026
Same journal

Preface.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides: From permeability assay toolbox to data-driven discovery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from phage display.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Physiological strategies for brain delivery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from natural proteins.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

In vitro blood-brain barrier models for the study of brain shuttle peptide transport.

Advances in pharmacology (San Diego, Calif.)·2026
See all related articles

Area of Science:

  • Neuroendocrinology
  • Molecular Pharmacology

Background:

  • Amylin's distinct pharmacology and localization to brain regions like the nucleus accumbens were known, but its receptor remained elusive for over a decade.
  • Initial cloning efforts suggested a similarity between the unknown amylin receptor and the calcitonin receptor, hinting at a shared molecular basis.
  • The identification of receptor activity modifying proteins (RAMPs) was crucial in resolving the enigma of the amylin receptor.

Purpose of the Study:

  • To elucidate the molecular identity and subtypes of the amylin receptor.
  • To understand the role of receptor activity modifying proteins (RAMPs) in mediating amylin's actions.
  • To characterize the pharmacology of different amylin receptor subtypes and their distribution in the brain and periphery.

Main Methods:

Related Experiment Videos

  • Investigated the interaction between calcitonin receptors (CTRs) and receptor activity modifying proteins (RAMPs) to determine their role in amylin receptor formation.
  • Utilized pharmacological profiling with various ligands, including salmon calcitonin (sCT), amylin, calcitonin gene-related peptide (CGRP), and mammalian calcitonin (CT), to differentiate receptor subtypes.
  • Examined the distribution of amylin binding sites in the brain (nucleus accumbens, subfornical organ, area postrema) and peripheral tissues (renal cortex).

    • Main Results:

    • Receptor activity modifying proteins (RAMPs) associate with calcitonin receptors, altering their pharmacology to become amylin-preferring, thus forming amylin receptors.
    • Two predominant amylin receptor subtypes were identified: amylin 1 (a) receptor (CTa + RAMP1) found in the nucleus accumbens and subfornical organ, and amylin 3 (a) receptor (CTa + RAMP3) in the area postrema.
    • Amylin binding sites are dense in circumventricular organs (subfornical organ, OVLT, area postrema) likely responding to circulating amylin, while binding in the nucleus accumbens may involve a different ligand due to the blood-brain barrier.

    Conclusions:

    • The identification of RAMPs in association with calcitonin receptors has solved the enigma of the amylin receptor, revealing at least six potential subtypes.
    • The characterized amylin receptor subtypes (amylin 1 (a) and amylin 3 (a)) exhibit distinct pharmacological profiles and tissue distribution, particularly in key brain regions.
    • Further research is needed to determine the precise functions of these amylin receptors and whether RAMPs modulate other receptor systems beyond the CT/CLR family.